['type 1 diabetes mellitus']
['biochaperone human insulin (hinsbet®)', 'insulin lispro (humalog®)', 'regular human insulin (huminsulin® normal)']

        Inclusion Criteria:

          -  Male or female subject aged 18-64 years (both inclusive).

          -  Type 1 diabetes mellitus (as diagnosed clinically) >= 12 months.

          -  Treated with multiple daily insulin injections or CSII >= 12 months.

          -  Current total daily insulin treatment < 1.2 (I)U/kg/day.

          -  Current total daily bolus insulin treatment < 0.7 (I)U/kg/day.

          -  BMI 18.5-28.0 kg/m^2 (both inclusive).

          -  HbA1c <= 9.0 % by local laboratory analysis

          -  Fasting C-peptide <= 0.30 nmol/L.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to IMPs or related products.

          -  Type 2 diabetes mellitus.

          -  Previous participation in this trial. Participation is defined as randomised.

          -  Participation in any clinical trial within 3 months prior to this trial.

          -  Clinically significant abnormal haematology, coagulation, biochemistry, lipids, or
             urinalysis screening tests, as judged by the Investigator considering the underlying
             disease.

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator.

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the Investigator might change gastrointestinal motility and food absorption.

          -  Unusual meal habits and special diet requirements or unwillingness to eat the food
             provided in the trial.

          -  Females of childbearing potential who are pregnant, breast-feeding or intend to become
             pregnant or are not using highly effective contraceptive methods
      